Articles tagged "Co-stimulation"

2021 American Transplant Congress
Infectious Complications After Belatacept Conversion in Kidney Transplant
J. E. Marvin¹, D. Amenyedor¹, M. M. Azar², K. Belfield¹, V. Do¹, R. Formica³, E. Cohen¹
¹Pharmacy, Yale New Haven Hospital, New Haven, CT, ²Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, ³Section of Nephrology, Yale School of Medicine, New Haven, CT
*Purpose: Tacrolimus (tac), a calcineurin inhibitor, is associated with multiple adverse effects when used for immunosuppression following kidney transplant (KT). Belatacept (bela) is a monoclonal…
2021 American Transplant Congress
A Comparison of Belatacept Conversion Regimens from Calcineurin Inhibitor-Based Immunosuppression
E. Huang, A. Vo, A. Peng, R. Najjar, S. Sethi, S. Jordan
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Outcomes with varying belatacept conversion protocols from calcineurin inhibitor (CNI)-based immunosuppression have been published but no standard protocol has been established. Beginning in 2012,…
2020 American Transplant Congress
Analysis of Rejection, Rejection Therapy and Renal Function in the BEST Trial
H. Kuzaro¹, A. R. Shields², A. Wiseman³, S. Tremblay¹, A. Christianson¹, D. Kaufman⁴, J. Leone⁵, A. Matas⁶, P. West-Thielke⁷, R. R. Alloway¹, E. S. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²The Christ Hospital, Cincinnati, OH, ³U Colorado, Denver, CO, ⁴U Wisconsin, Madison, WI, ⁵Tampa General, Tampa, FL, ⁶U Minnesota, Minneapolis, MN, ⁷UIC, Chicago, IL
*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal) compared two belatacept (BELA)-based early corticosteroid withdrawal (ESW) regimens and alemtuzumab (ALEM) or rabbit antithymocyte globulin (rATG)…
2020 American Transplant Congress
Effector Differentiation of Endogenous Antigen-Specific CD8⁺ T Cells is Selectively Limited by CTLA-4 Ig
S. M. Krummey, K. P. Tong, M. L. Ford
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA
*Purpose: Costimulation blockade with belatacept (CTLA-4 Ig) offers improved renal function and reduced toxicity following transplantation compared to calcineurin inhibitors. Nonetheless, episodes of acute T…
2020 American Transplant Congress
Two Pilot Studies Exploring the Diagnostic and Predictive Potential of Serum LAG3 and FGL1 in Kidney Transplant Recipients
Y. Li¹, L. Yan¹, Y. Li¹, C. Yang¹, Z. Wan¹, Y. An¹, Y. Bai¹, L. Wang¹, Y. Shi²
¹Department of Laboratory Medicine, West China Hospital, Chengdu, China, ²Department of Nephrology, West China Hospital, Chengdu, China
*Purpose: Lymphocyte activation gene 3 (LAG3), an immune checkpoint, plays an important role in the negative regulation of immune response and the induction of immune…
2020 American Transplant Congress
Belatacept Provides Superior Inhibition of Donor Specific Antibody Formation in Kidney Transplant Recipients with Acute Rejection
O. Cristea, C. Larsen, I. Badell
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA
*Purpose: The factors responsible for chronic renal allograft dysfunction and premature graft loss are incompletely understood and likely multifactorial. Immunologic injury partially attributable to the…
2020 American Transplant Congress
Belatacept Combined with BTLA Prolong Allogeneic Kidney Graft Survival and Inhibited Acute Rejection after Kidney Transplantation
H. Zhang, Z. Wang, J. Zhang, Z. Han, J. Tao, H. Chen, L. Sun, R. Tan, M. Gu
Jiangsu Province Hospital, Nanjing, China
*Purpose: Belatacept as a high-affinity variant of CTLA-4Ig, has been applied into kidney transplantation to against acute rejection. However, adoption of Belatacept has been limited…
2020 American Transplant Congress
Naïve B Cells Regulation by TLR-Breg Cells In Vitro
Q. Fu, K. Lee, G. Huai, K. Deng, N. J. Feeney, C. Leguern, S. Deng, J. F. Markmann
Center for Transplant Science, MGH, Boston, MA
*Purpose: Regulatory B cells (Bregs) have shown great potential in cell therapies for murine organ transplantation by inhibiting the proliferation of cytotoxic and helper T…
2020 American Transplant Congress
Costimulatory Signal Impacts Car Treg Fate and Function in Transplantation
B. Lamarthée¹, A. Marchal¹, S. Charbonnier¹, T. Blein¹, K. Vogt², M. Titeux¹, N. Pallet³, M. Delville¹, E. Six¹, D. Anglicheau⁴, C. Legendre⁴, B. Sawitzki², J. Taupin⁵, M. Cavazzana¹, I. André¹, J. Zuber¹
¹Inserm U1163, Institut Imagine, Paris, France, ²Department of Immunology, Charité University Hospital, Berlin, Germany, ³Inserm U1147, Centre Universitaire des Saints Pères, Paris, France, ⁴Service de Transplantation Rénale Adulte, Assistance Publique–Hôpitaux de Paris, Hôpital Necker, Paris, France, ⁵Inserm U1160, Centre Hayem, Paris, France
*Purpose: Donor-specific regulatory T-cell (Treg) therapy has emerged as a potent strategy to promote immune tolerance in experimental transplantation. However, a major stumbling block in…
2020 American Transplant Congress
Outcomes of De Novo Belatacept-Based Immunosuppression in Recipients of Kidneys at High Risk for Delayed Graft Function in the Setting of Lymphocyte Depleting Immune Modulation
T. L. Shertel¹, M. A. Wynd¹, M. A. Pereiras¹, J. T. McKeen¹, Y. Y. Yushkov², B. R. Schleich³, S. E. Geatrakas², A. Patel², M. J. Goldstein²
¹Pharmacy, Hackensack University Medical Center, Hackensack, NJ, ²Organ Transplant, Hackensack University Medical Center, Hackensack, NJ, ³Patient Safety and Quality, Hackensack University Medical Center, Hackensack, NJ
*Purpose: Our center created an immunosuppression protocol using de novo belatacept (DNB) in the setting of lymphocyte depletion to increase the utilization of deceased donor…

« Previous Page
1
…
4
5
6
7
8
…
30
Next Page »